Cargando…

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease

BACKGROUND: Currently available treatments for Alzheimer’s disease (AD) can produce mild improvements in cognitive function, behavior, and activities of daily living in patients, but their influence on long-term survival is not well established. This study was designed to assess patient survival and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hager, Klaus, Baseman, Alan S, Nye, Jeffrey S, Brashear, H Robert, Han, John, Sano, Mary, Davis, Bonnie, Richards, Henry M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937252/ https://www.ncbi.nlm.nih.gov/pubmed/24591834 http://dx.doi.org/10.2147/NDT.S57909

Ejemplares similares

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
por: Hager, Klaus, et al.
Publicado: (2016)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Publicado: (2014)

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial
por: Prins, Niels D, et al.
Publicado: (2014)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer’s Disease
por: Kavanagh, S, et al.
Publicado: (2011)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study
por: Zhang, Zhenxin, et al.
Publicado: (2012)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
por: Woo, Fong Yen, et al.
Publicado: (2015)

Pre-sleep treatment with galantamine stimulates lucid dreaming: A double-blind, placebo-controlled, crossover study
por: LaBerge, Stephen, et al.
Publicado: (2018)

Pharmacological investigations of new galantamine peptide esters
por: Tsvetkova, Dobrina, et al.
Publicado: (2014)

Galantamine as a Treatment Option for Nicotine Addiction
por: Jamali, Qutub
Publicado: (2021)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)

Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Bhattacharya, Soumee, et al.
Publicado: (2014)

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease
por: Reggiani, Angelo M., et al.
Publicado: (2016)

PT596. The comparison with galantamine and donepezil on Alzheimer’s Disease patients and its relationship with cerebral blood flow
por: Wake, Rei, et al.
Publicado: (2016)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
por: Castillo, Willian O., et al.
Publicado: (2017)

Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy
por: Nanaki, Stavroula G., et al.
Publicado: (2020)

Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
por: Rajkumar, Manickam, et al.
Publicado: (2022)

Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease
por: Baakman, Anne Catrien, et al.
Publicado: (2022)

Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy
por: Georgieva, Dilyana, et al.
Publicado: (2023)

The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer's Disease
por: Lee, Jae-Hong, et al.
Publicado: (2015)

Effect of galantamine on platelet functions in healthy elderly people
por: Isik, Ahmet Turan, et al.
Publicado: (2013)

Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity
por: Alsikhan, Rawan S., et al.
Publicado: (2023)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano, Osamu, et al.
Publicado: (2013)

Mild cognitive disorder and depression: treatment with combination of galantamine and escitalopram
por: Zarra, Julio, et al.
Publicado: (2010)

Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine
por: Koola, Maju Mathew
Publicado: (2016)

The case of galantamine: repurposing and late blooming of a cholinergic drug
por: Mucke, Hermann AM
Publicado: (2015)

Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d3pamg4bodl5ou4jau2egl6es7